Signaling by ERBB2 in Cancer
Subramanian J, Katta A, Masood A, Vudem DR, Kancha RK. Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid Cancers. 2019 Jul 10;24(12):e1303–14. doi: 10.1634/theoncologist.2018-0845.; Croessmann S, Formisano L, Kinch LN, Gonzalez-Ericsson PI, Sudhan DR, Nagy RJ, Mathew A, Bernicker EH, Cristofanilli M, He J, Cutler RE, Lalani AS, Miller VA, Lanman RB, Grishin NV, Arteaga CL. Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer. Clin Cancer Res. 2019 Jan 01;25(1):277–89. PMID: 30314968; PMCID: PMC6320312.; Pahuja KB, Nguyen TT, Jaiswal BS, Prabhash K, Thaker TM, Senger K, Chaudhuri S, Kljavin NM, Antony A, Phalke S, Kumar P, Mravic M, Stawiski EW, Vargas D, Durinck S, Gupta R, Khanna-Gupta A, Trabucco SE, Sokol ES, Hartmaier RJ, Singh A, Chougule A, Trivedi V, Dutt A, Patil V, Joshi A, Noronha V, Ziai J, Banavali SD, Ramprasad V, DeGrado WF, Bueno R, Jura N, Seshagiri S. Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations. Cancer Cell. 2018 Nov 12;34(5):792–806.e5. PMID: 30449325; PMCID: PMC6248889.; Nagano M, Kohsaka S, Ueno T, Kojima S, Saka K, Iwase H, Kawazu M, Mano H. High-Throughput Functional Evaluation of Variants of Unknown Significance in ERBB2. Clin Cancer Res. 2018 Oct 15;24(20):5112–22. doi: 10.1158/1078-0432.ccr-18-0991. PMID: 29967253.; Hanker AB, Brewer MR, Sheehan JH, Koch JP, Sliwoski GR, Nagy R, Lanman R, Berger MF, Hyman DM, Solit DB, He J, Miller V, Cutler RE, Lalani AS, Cross D, Lovly CM, Meiler J, Arteaga CL. An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer. Cancer Discov. 2017 Jun;7(6):575–85. PMID: 28274957; PMCID: PMC5457707.; Ou SI, Schrock AB, Bocharov EV, Klempner SJ, Haddad CK, Steinecker G, Johnson M, Gitlitz BJ, Chung J, Campregher PV, Ross JS, Stephens PJ, Miller VA, Suh JH, Ali SM, Velcheti V. HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib. J Thorac Oncol. 2017 Mar;12(3):446–57. doi: 10.1016/j.jtho.2016.11.2224. PMID: 27903463.; Hu Z, Hu Y, Liu X, Xi R, Zhang A, Liu D, Xie Q, Chen L. Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor. Oncotarget. 2015 Oct 13;6(31):31628–39. PMID: 26375550; PMCID: PMC4741629.; Hu Z, Wan X, Hao R, Zhang H, Li L, Li L, Xie Q, Wang P, Gao Y, Chen S, Wei M, Luan Z, Zhang A, Huang N, Chen L. Phosphorylation of Mutationally Introduced Tyrosine in the Activation Loop of HER2 Confers Gain-of-Function Activity. PLoS ONE. 2015 Apr 08;10(4):e0123623. doi: 10.1371/journal.pone.0123623.; Rexer BN, Ghosh R, Narasanna A, Estrada MV, Chakrabarty A, Song Y, Engelman JA, Arteaga CL. Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2. Clin Cancer Res. 2013 Oct 01;19(19):5390–401. PMID: 23948973; PMCID: PMC3809918.; Collier TS, Diraviyam K, Monsey J, Shen W, Sept D, Bose R. Carboxyl Group Footprinting Mass Spectrometry and Molecular Dynamics Identify Key Interactions in the HER2-HER3 Receptor Tyrosine Kinase Interface. Journal of Biological Chemistry. 2013 Aug;288(35):25254–64. doi: 10.1074/jbc.m113.474882.; Bose R, Kavuri SM, Searleman AC, Shen W, Shen D, Koboldt DC, Monsey J, Goel N, Aronson AB, Li S, Ma CX, Ding L, Mardis ER, Ellis MJ. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov. 2013 Feb;3(2):224–37. PMID: 23220880; PMCID: PMC3570596.; Greulich H, Kaplan B, Mertins P, Chen T, Tanaka KE, Yun C, Zhang X, Lee S, Cho J, Ambrogio L, Liao R, Imielinski M, Banerji S, Berger AH, Lawrence MS, Zhang J, Pho NH, Walker SR, Winckler W, Getz G, Frank D, Hahn WC, Eck MJ, Mani DR, Jaffe JD, Carr SA, Wong K, Meyerson M. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc. Natl. Acad. Sci. U.S.A. 2012 Aug 20;109(36):14476–81. doi: 10.1073/pnas.1203201109.; Kancha RK, von Bubnoff N, Bartosch N, Peschel C, Engh RA, Duyster J. Differential Sensitivity of ERBB2 Kinase Domain Mutations towards Lapatinib. PLoS ONE. 2011 Oct 28;6(10):e26760. doi: 10.1371/journal.pone.0026760.; Spears M, Taylor KJ, Munro AF, Cunningham CA, Mallon EA, Twelves CJ, Cameron DA, Thomas J, Bartlett JMS. In situ detection of HER2:HER2 and HER2:HER3 protein–protein interactions demonstrates prognostic significance in early breast cancer. Breast Cancer Research and Treatment. 2011 Jun 03;132(2):463–70. doi: 10.1007/s10549-011-1606-z.; Pickl M, Ries CH. Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab. Oncogene. 2009 Jan 22;28(3):461–8. doi: 10.1038/onc.2008.394. PMID: 18978815.